Pure Bioscience (PURE) Stock Statistics & Valuation Metrics

Pure Bioscience has a market cap or net worth of $5.20M. The enterprise value is $10.37M.

Pure Bioscience has 111,886,480 shares outstanding. The number of shares has decreased by -2.65% in one year.

Pure Bioscience’s return on equity (ROE) is <0.01 and return on invested capital (ROIC) is -1.89%.

The current PE Ratio of Pure Bioscience is ―. Pure Bioscience’s PEG ratio is 0.15.

In the last 12 months, Pure Bioscience had revenue of 2.20B and earned -2.40M in profits. Earnings per share was -0.02.

In the last 12 months, operating cash flow was -1.76M and capital expenditures 0.00, giving a free cash flow of -1.76M billion.

Pure Bioscience pays an annual dividend of ―, resulting in a dividend yield of ―

Pure Bioscience upcoming earnings date is Mar 18, 2026, After Close (Confirmed).

Pure Bioscience as a current ratio of 1.12, with Debt / Equity ratio of -102.36%

In the past 12 months, Pure Bioscience has paid 0.00 in taxes.

Pure Bioscience EV to EBITDA ratio is -2.34K, with an EV/FCF ratio of -2.44.

Pure Bioscience has $509.00K in cash and marketable securities with $5.68M in debt, giving a net cash position of -$5.17M billion.

Gross margin is 55357.90%, with operating margin of -0.10%, and net profit margin of -0.11%.

The average price target for Pure Bioscience is ―, which is 11.43% higher than the current price. The consensus rating is ―